The article discusses the impact of activating mutations in the EGFR gene in lung adenocarcinoma, specifically how these mutations lead to sensitivity to targeted therapies like TKIs. Despite this, resistance mechanisms can arise, complicating treatment. A case study is provided of a 44-year-old woman whose EGFR mutation was lost after treatment with osimertinib combined with a personalized neopeptide vaccine aimed at her tumor. This highlights the potential of combining traditional and novel immunotherapies for better patient outcomes.
A 44-year-old woman with stage IIIB lung adenocarcinoma lost her clonal EGFR ex19del mutation after treatment with osimertinib and a personalized neopeptide vaccine.
The combination of targeted therapies like osimertinib and emerging personalized immunotherapies may change the therapeutic landscape for EGFR mutant lung cancer.
Resistance to EGFR TKIs often emerges via secondary mutations or alternative pathways, challenging sustained therapeutic responses in lung adenocarcinoma patients.
Investigating immune responses and understanding mechanisms of immune evasion can pave the way for novel treatment strategies in resistant EGFR mutant lung cancers.
Collection
[
|
...
]